LEADER 03960nam 2200625 450 001 9910787308103321 005 20230801231314.0 010 $a0-309-26119-8 010 $a0-309-26117-1 035 $a(CKB)2670000000410074 035 $a(EBL)3379066 035 $a(SSID)ssj0000746505 035 $a(PQKBManifestationID)11447835 035 $a(PQKBTitleCode)TC0000746505 035 $a(PQKBWorkID)10861620 035 $a(PQKB)11316072 035 $a(MiAaPQ)EBC3379066 035 $a(Au-PeEL)EBL3379066 035 $a(CaPaEBR)ebr10863714 035 $a(OCoLC)829421146 035 $a(EXLCZ)992670000000410074 100 $a20130212h20122012 uy| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aMaximizing the impact of the Cures Acceleration Network $eaccelerating the development of new drugs and diagnostics : workshop summary /$fSteve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies 210 1$aWashington, District of Columbia :$cNational Academies Press,$d[2012] 210 4$dİ2012 215 $a1 online resource (132 p.) 300 $aDescription based upon print version of record. 311 $a0-309-26116-3 320 $aIncludes bibliographical references (pages 71). 327 $aIntroduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN. 330 $aAdvances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description. 606 $aDrug monitoring 606 $aDrug development$zUnited States 606 $aDrugs$zUnited States$xDesign 606 $aPharmaceutical industry$zUnited States$xQuality control 615 0$aDrug monitoring. 615 0$aDrug development 615 0$aDrugs$xDesign. 615 0$aPharmaceutical industry$xQuality control. 676 $a615.1/9 702 $aOlson$b Steve$f1956- 702 $aClaiborne$b Anne B. 712 02$aNational Institute of Medicine (U.S.).$bBoard on Health Sciences Policy, 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910787308103321 996 $aMaximizing the impact of the Cures Acceleration Network$93829043 997 $aUNINA